Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ExPEC4V in Healthy Adults
NCT02546960Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2015
- Primary completion
- Sep 2016
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of ExPEC4V in invasive extraintestinal pathogenic Escherichia coli disease (IED), sponsored by Janssen Pharmaceutical. Started Nov 2015; status: completed.
02
Drugs
ExPEC4V
03
Conditions
invasive extraintestinal pathogenic Escherichia coli disease (IED)
Beyond the preview
Go deeper on NCT02546960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02546960.